Very recently, it was reported that activated NKT cells decrease the frequency and immunosuppressive activity of MDSCs in tumor‐bearing mice.22 In an animal model, activated NKT cells converted MDSCs into immunogenic APCs.23 Using peripheral blood mononuclear cells (PBMC) of patients with early stage breast cancer, we also demonstrated that conversion of MDSCs to CD33+CD11b−/lowHLA‐DR+ APCs, in vitro, was associated with an increased frequency of CD25+ NKT cells in reprogrammed immune cells.24 Here, CD33 is linked to neoplasm.